New pathogenic mechanisms in diabetic wound healing by Sunkari, Vivekananda
From DEPARTMENT OF MOLECULAR MEDICINE AND 
SURGERY
Karolinska Institutet, Stockholm, Sweden
NEW PATHOGENIC MECHANISMS IN 
DIABETIC WOUND HEALING
          Vivekananda Gupta Sunkari
     ȇĺÂĥfV3T EWŠ di3Cĸ
     Stockholm 2012
All previously published papers were reproduced with permission from the publisher.
Published by Karolinska Institutet. Printed by [Universitetsservice US-AB]
© Vivekananda Gupta Sunkari, 2012
ISBN 978-91-7457-911-6
 
 
 
 
 
 
                        Dedicated to all the MICE I have used for my experiments

ABSTRACT
Diabetic foot ulcers (DFU) represent one of the most feared and invalidating 
complication of diabetes with high financial pressure for the healthcare system. For the 
moment there is no specific therapy available and it has become a priority to develop 
novel rational therapeutic strategies based on new pathophysiological mechanisms. Our 
focus was therefore to delineate relevant pathogenic pathways specifically deregulated 
in diabetes that could contribute to the defective wound healing in diabetes. Cellular 
proliferation, migration and differentiation, angiogenesis, extracellular matrix 
deposition, local recruitment of endothelial precursors cells are some of the essential 
processes activated during wound healing. We decided to focus our investigation on 
two central signaling pathways (HIF-1 pathway and Notch signaling) that modulates 
most of the above cellular events. 
Hypoxia plays an important role in the development of DFU. We showed that 
hyperglycemia complexly repressed the function of Hypoxia inducible Factor (HIF) 
which is the main cellular adaptor to low oxygen tension. The repressive effect of 
hyperglycemia on HIF-1 alpha was pVHL dependent and affected complexly its 
transactivation. This was mirrored by suppression of several HIF-1 target genes 
essential for wound healing. However, by blocking HIF-Į GHJUDGDWLRQ WKURXJK
chemical interference with HIF hydroxylases (DMOG or DFX), it was possible to 
reverse the repressive effect of hyperglycemia on HIF and to improve the wound 
healing process in a diabetic mouse model (the db/db mouse). Moreover, local 
adenovirus-mediated transfer of two stable HIF constructs demonstrated that 
stabilization of HIF-1alpha is necessary and sufficient for promoting wound healing in 
a diabetic environment. Hyperbaric oxygen therapy (HBOT) has been used as 
therapeutical option for severe foot ulcers, resistant to standard therapy. The detailed 
mechanisms activated by HBOT are however still unraveled. We showed that HBOT 
activated HIF-1alpha at several levels with functional consequence on cellular 
proliferation. Moreover, we could show that local transfer of a stable form of HIF has 
additive effect to HBOT improving wound healing in the db/db mice. 
Notch signaling is a cell-to-cell contact system that consists of several receptors (Notch 
1-4) and ligands with a high specific cell-dependent effect. Binding of the ligands to the 
receptors is followed by proteolytic cleavage of the receptor by a Ȗ-secretase complex 
which is followed by activation of the intracellular signaling. Here we show that 
hyperglycemia activated Notch signaling at several levels both in vitro and in vivo. The 
effect of hyperglycemia on Notch signaling is canceled in the presence of ɀ-secretase 
inhibitors with positive functional effect both on in vitro migration and on in vitro 
angiogenesis assays.  Moreover local treatment with ɀ-secretase inhibitors improved 
wound healing of db/db mice despite chronic hyperglycemia. The effect is specific 
    ɀ-secretase inhibitors nor immunization with a DNA 
vaccine against Dll4 influenced the wound healing in non-diabetic animals. Using a 
loss of function genetic approach (specific siRNA and cre/lox system) we showed that 
Notch 1 has a central pathogenic role in Notch dependent repression of wound healing 
in diabetes. 
In conclusion, we identified two new pathogenic mechanisms important for impaired
wound healing in diabetes. Our findings warrant development of specific therapeutics 
that address HIF and Notch signaling for normal healing of diabetic wounds.
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LIST OF SOME IMPORTANT ABBREVIATIONS
ARD Ankyrin repeat domain
ARNT Aryl hydrocarbon receptor nuclear translocator
bHLH Basic helix-loop-helix
CTAD C-terminal transactivation domain
DFU                 Diabetic foot ulcers
EPO Erythropoietin
EPAS Endothelial PAS domain protein
IPAS Inhibitory domain PAS protein
MAML1 Mastermind-like protein 1
LNRs Lin12/Notch repeats
NICD Notch intracellular domain
NTAD N-terminal transactivation domain
NLSs Nuclear localization sequences
ODD Oxygen-dependent degradation domain
OG Oxoglutarate
PEST Proline-glutamate-serine-threonine-rich
PHDs Prolyl hydroxylase domain proteins
pVHL Von Hippel–Lindau tumor suppressor protein
HBOT Hyperbaric oxygen therapy
Hes Hairy/enhancer-of-split
Hey Hairy/enhancer-of-split related with YRPW motif
HG High glucose or hyperglycemia
HIF Hypoxia-inducible factor
HRE Hypoxia responsive element
RAM RBP--ț-associated molecule
RBP-J Recombination signal sequence binding protein-Jkappa
ROS Reactive oxygen species
TAD Transactivation domain
VEGF Vascular Endothelial growth factor
11 INTRODCUTION
1.1 DIABETES
Diabetes mellitus (DM) is dramatically increasing worldwide. It is estimated that nearly 
250 million people are currently affected by DM worldwide and with an expected 
increase to 400 million in the near future according to the data from International 
Diabetes Federation (IDF) and the World Health Organization (WHO)1. The life time 
expectancy of patients with diabetes is on average 10% shorter than in non-diabetics 
individuals due to complications as the disease progresses2. An important complication 
in term of morbidity, mortality and financial costs is diabetic foot ulcers (DFU) 3.
1.2 EPIDEMOLOGY
Diabetic foot ulceration represents a major medical, social and economic problem and is 
coupled with a high rate of mortality3,4. Amputation rate in diabetes is almost 15 times 
higher when compared to the non-diabetic population5. About 85% of non-traumatic
amputations originate from DFU which is also the most common cause of 
hospitalization of diabetic patients6. DFU has also a high risk for recurrence. The annual 
incidence of diabetic foot ulcers is between 4 to 10% in diabetic population7-9. Almost 
25% of patients are at risk to develop foot ulcers during their life time9. The therapeutic
options available nowadays are restricted to off-loading, treatment of infection and
improvement of blood circulation. However even with the best clinical care, the time to
heal is longer than 3 months and there are up to 10% of the patients who eventually
undergo amputation4,10.
1.3 ETIOLOGY
The etiology of diabetic foot ulcers is multifactorial. Diabetic neuropathy and ischemia 
are central contributors to the development of DFU. Impaired blood flow due to micro 
and macro angiopathy leads to impaired tissue nutrition that makes the skin more 
susceptible to trauma. 
Neuropathy plays an essential role in the development of DFU. Most of the plantar 
ulcerations are preceded by distal symmetrical polyneuropathy11,12. Motor neuropathy 
2affects the small muscles of the foot and causes weakness, atrophy, and deformity that 
create areas exposed to high pressure. Reduction in sweating as a consequence of
autonomic neuropathy eventually results in drying and fissuring of the skin and 
consequent ulceration13. Autonomic neuropathy is also the most common predictor of 
DFU14. Moreover, peripheral autonomic neuropathy and hyperglycemia lead to 
impaired skin microcirculation15,16. Sensory neuropathy is an important predisposing 
factor because it leaves the patients to be exposed to trauma without protective 
reaction of avoidance. Improper footwear, puncture wounds and foreign bodies in 
footwear undetected because of lack of sensation result in increased pressure and may 
lead to ulceration17-19. Substantial evidence shows that repetitive pressure result in 
tissue breakdown and poor healing20-23. Callus formation is often seen in patients with 
diabetic foot exposed to repeated pressure and  increase significantly the risk of 
developing DFU on the same area24.
Arterial insufficiency is also important in the defective wound healing in DFU due to 
the reduction of oxygen supply and nutrition essential for healing 25. About 46% of 
amputations in patients with diabetic foot ulcers are due to arterial insufficiency26,27.
Infection in the DFU contributes also negatively to the regenerative capacity of the 
tissues. Two thirds of patients with diabetic foot ulcers are affected by osteomyelitis 
with its specific therapeutic challenges28.
1.4 THE WOUND HEALING PROCESS IN DIABETES
The wound healing process consists of several phases: inflammation, proliferation, 
granulation and tissue remodeling29. Wound healing represent a cellular response to 
injury and involves activation of several cells i.e. fibroblasts, endothelial cells, 
macrophages, and platelets. Several growth factors and cytokines are released in a 
perfectly coordinated manner during the healing process30. The first step in wound 
healing after injury is the clot formation, initiated by release of several factors such as 
TGF beta and PDGF-% which help in recruiting fibroblasts and leukocytes to the 
wound area31.  The Inflammatory phase lasts around 4 days and macrophages play a 
vital role in this phase. Recently a central role in the inflammatory phase was 
identified for the plasma protein plasminogen32. Macrophages migrate to the wound 
3area and engulf necrotic material and then produce factors that induce angiogenesis by 
endothelial cells, epithelialization by keratinocytes and matrix deposition by 
fibroblasts producing collagen, a major component of extra cellular matrix (ECM)33,34.
Local endothelial cells migrate to form capillary sprouts35. Endothelial progenitor cells 
derived from bone marrow, home at the site of injury, undergo in situ differentiation
and contribute to vasculogenesis36. Granulation, re-epithelisation and wound 
contraction are also important processes of wound healing37. Granulation tissue is the
fibrous connective tissue, composed of fibroblasts, that typically grows from the base 
of the wound and they mainly secrete type III collagen38. Granulation is followed by 
epithelisation; during this process epithelial cells and keratinocytes migrate across the 
wound barrier and granulation tissue. Epithelial cells proliferate and form a sheet 
across the edges of the wound38.
Contraction is also an important step in wound healing39 where myofibroblasts and 
fibroblasts are vital contributors. They are stimulated by growth factors and are attracted 
by fibronectin to move along the fibrin on extracellular matrix to wounds edges. 
Successful contraction eventually signals for tissue remodeling which is the last phase of 
wound healing where type 1 collagen has an important role in organizing the collagen 
fibers in a process that may last from several days to months40.
Diabetes alters several mechanisms at cellular and molecular levels that lead to impaired 
wound healing process30,41. Hyperglycemia leads to impairment in migration42 and 
angiogenesis43,44, dysfunction of macrophages45, imbalance in ECM components and 
their remodeling by MMPs46, impaired growth factor production44,47,48 etc. Markers for 
delayed wound healing such as c-myc and beta-catenin that have repressive effects on 
migration of keratinocytes were suggested to be used in order to identify chronic 
wounds with low potential to spontaneous healing49. Endothelial progenitor cells (EPC) 
replace lost cells at the site of tissue injury. EPCs are critical in neovascularization and 
play a central role in wound healing, but their circulating levels and their number at the 
site of the wounds are decreased in diabetes and contribute to a delay in wound 
healing50.
41.5 HIF SIGNALING PATHWAY
1.5.1 Hypoxia
Hypoxia, defined as a lower oxygen concentration, can be generalized or localized and it 
is the consequence of either inadequate oxygen supply or increased oxygen 
consumption. Hypoxia plays an important role in several essential processes such as 
angiogenesis by triggering vessel growth and promoting vascular bed expansion51 and 
playing roles in cell fate decision52,53. The molecular reaction to hypoxia is mediated by 
a transcriptional factor called hypoxia-inducible factor (HIF). HIF activates 
approximately 100 target genes, which play central physiological roles in response to 
hypoxia (figure 1)54,55
Figure1: HIF-1 activates several genes with central roles in the reaction to hypoxia
51.5.2 Hypoxia Inducible factors
HIF is a heterodimeric transcription factor first discovered as a regulator of 
erythropoietin production56. The heterodimeric complex is composed of two 
constitutively expressed subunits: an alpha subunit regulated by oxygen and a beta 
subunit also called aryl receptor nuclear translocator (ARNT)57. HIF belongs to the basic
helix-loop-helix (bHLH)-Per-ARNT-Sim (PAS) protein family58. The HIF-1 alpha 
subunit is composed of two transactivation domains, namely NTAD (N-terminal 
transactivation domain) and CTAD (C-terminal transactivation domain). HIF-1 alpha 
stability is negatively regulated in normoxia at the oxygen dependent degradation 
domain (ODD) which is found in NTAD59. The N-terminal bHLH is rich in residues that 
involved in DNA binding60-62. Co-factors such as CBP/p300 interact with both HIF-1
alpha transactivation domains to activate gene transcription63-65.
Three isoforms of HIF – alpha subunits have been identified (HIF-1 alpha, HIF-2
alpha/EPAS1, HIF-3 alpha) and three HIF- beta subunits (ARNT, ARNT2 , ARNT3) 
(figure 2). The overall similarity between HIF-1 and HIF-2 is about 48% in their amino 
acid composition. HIF-1 alpha contains 826 amino acids while HIF-2 alpha has 870 
amino acids with longer N-terminal region than HIF-1 alpha66,67. The transactivation 
domains at the C-terminal region have the highest similarity between the isoforms68.
Figure 2: HIF-alpha Isoforms
6HIF-3 alpha has a different overall structure but with similar N-terminal region that 
permits dimerization with HIF-1 beta which is followed by binding to the hypoxia 
responsive element (HRE). Unlike HIF-1/2, HIF-3 alpha lacks CTAD region and is 
regarded as a dominant negative regulator of HIF signaling69,70. Availability of ARNT is 
crucial for HIF-3 alpha actions71. HIF-3 alpha has been identified as a HIF-1 target 
gene72 and is also uniquely regulated at the transcription level since HIF-3 mRNA 
increases under hypoxic conditions73.
The expression pattern of HIF-1 alpha and ARNT is ubiquitous, while the other 
members have a restricted pattern of expression74. HIF-2 alpha is expressed in 
endothelial cells, hepatocytes, cardiomyocytes66,75, while HIF-3 alpha is expressed in 
heart, brain, lung, kidney and adult thymus76.
1.5.3 Regulation of HIF-1 protein stability
HIF-1 beta (ARNT) is constitutively expressed irrespective of oxygen levels77,78 but 
only HIF-1 alpha is degraded in normoxia via proteasomal degradation (figure 3). In the 
presence of oxygen, HIF-1 alpha is hydroxylated on at least one of the two conserved 
proline residues within the ODD (oxygen degradation domain) by prolyl hydroxylases 
(PHDs)79-82. The hydroxylated HIF-1 alpha is identified by von Hippel-Lindau tumor 
suppressor protein (pVHL) and eventually ubiquitinylated leading to its degradation by 
the 26S proteasome83,84.  These proline residues which are sensitive to oxygen are 
conserved in all three isoforms of HIF alpha subunits, HIF-1 alpha (402 and 564), the 
proline residues in HIF-2 alpha and HIF-3 alpha (405 and 530).  Three isoforms of 
PHDs have been identified (PHD1, PHD2 and PHD3) and belong to the dixoygenase 
super family, requiring together with oxygen two cofactors (2-oxoglutarate and iron) for 
performing its activity 82,85-88,. PHD2 seems to be the most important PHD2 for 
regulation of HIF stability in normoxia89, but the expression pattern and distribution of 
PHDs members are tissue and cell specific90-92.     
7                          Figure 3: Classical HIF-1 alpha regulation.
Interestingly PHDs are induced by HIF-1 in prolonged hypoxia closing a regulatory 
feed-back loop93.
HIF-1 alpha is also regulated by other factors besides the canonical regulation through 
PHDs. Acetylation of Lys 532 by Arrest defective protein-1 (ARD1) that is modulated 
by oxygen, enhances interaction of HIF-ĮZLWKS9+/DQGVXEVHTXHQWO\OHDGVWR+,)-
Į GHJUDGDWLRQ94. However, metastasis-associated protein 1 (MTA1) counteracts the 
activity of ARD1 by binding to HIF-ĮDQGHQKDQFLQJ WKH VWDELOLW\RI+,)-1 alpha95.
Protein SSAT2 promotes ubiquitination of HIF-1 alpha by interacting with HIF-1 alpha, 
pVHL and elongin C96. Osteo Sarcoma protein-9 (OS9) initiates a strong binding 
between HIF-1 and PHD2 ensuring a stable complex formation and enabling a perfect 
degradation pathway97. The affinity of pVHL to HIF-1 alpha binding is decreased by 
Hepatitis B virus X protein (HBx), a protein involved in hepatocellular carcinoma 
development, interacts with the bHLH/PAS domain of HIF-1 and decreases its binding 
to pVHL, thereby increasing stability of HIF-1 alpha98. Bafilomycin stimulation allows 
ATP6V0C interaction with HIF-1 alpha and directly competes with pVHL in binding to 
HIF-1 alpha99. The pVHL-interacting deubiquitinating enzyme 2 (VDU2) interacts with 
the HIF-1 alpha and pVHL complex and reverses the ubiquitination process and 
stabilizes HIF-1 alpha100. Insulin like growth factor -1 (IGF-1) induced accumulation of 
both HIF-1 alpha and HIF-2 and followed by an increase in HIF function101,102.
8SIRT3, one of the proteins from the Sirtuin family destabilizes HIF-1 alpha in a PHD 
dependent manner. It has been shown that SIRT2 destabilizes HIF-1 alpha by inhibiting 
ROS production, promoting secondary maximal PHD activity103. Reactive oxygen 
species (ROS) play a key role in HIF-1 alpha stability; it has been shown that ROS 
directly affects PHDs enzymatic activity by preventing hydroxylation of HIF104; ROS 
generated from the mitochondrial complex were suggested to play a special role in HIF 
stabilization105. However, the specific role and relative significance of ROS in mediating 
the hypoxic response remain unclear and contradictory, as lower levels of ROS were 
detected in hypoxia than in normoxia106.
HIF-1 alpha is also regulated independently of the pVHL mechanism through several 
interacting proteins. Geldanamycin which is an HSP90 antagonist promotes 
ubiquitination and proteasomal degradation of HIF-ĮE\GLVUXSWLQJLWVDVVRFLDWLRQZLWK
HSP90, in renal carcinoma cell lines via a PHD2/pVHL-independent pathway107.
RACK1 binds to HIF-1 alpha and promotes its degradation independent of pVHL108.
This process can be enhanced by SSAT1 (Spermidine/spermine N(1)-acetyltransferase 
1) stabilizing interaction of HIF-1 alpha to RACK1 109. RACK1 competes with HSP90 
in binding to HIF-1 alpha thereby promoting a VHL independent degradation108.
Binding of p53 to a HIF and p300 transcriptional complex mediates inhibition of HIF 
activity110, HIF-Į-p53 interaction is modulated by several proteins such as Mdm2 
(murine double minute, functions as E3-ubiquitin ligase and negatively regulate p53 
actions)111 or Jun activation domain-binding protein-1 (Jab1), a coactivator of AP-1
transcription factor interacts directly with HIF-1 alpha and increased transcription and 
stability of HIF-1 alpha protein, through modulation of HIF-Į-p53 interaction112,113.
Small ubiquitin-related modifier (SUMO) modulates also HIF-1 alpha stability. It has 
been shown that hypoxia induces SUMOylation of HIF-1 by binding it to the pVHL-E3 
complex which leads to HIF-1 to degradation114. On the other hand RSUME which is an 
inducer of SUMOylation increases SUMO conjugation with HIF-1 alpha in hypoxia and 
stabilizes HIF-1 alpha115. The data available to date about SUMO and HIF-1 alpha 
regulation are confusing and further research is needed to understand the exact role of 
SUMOylation.
91.5.4 Regulation of HIF-1 alpha transcriptional activity
The transcriptional activity of HIF-1 alpha is modified and regulated by many 
interacting proteins; HIF-1 alpha forms a heterodimeric complex with ARNT and binds 
to promoter of hypoxia responsive elements (HREs) in the nucleus to express its 
downstream target genes 116. Factor inhibiting HIF (FIH) hydroxylates asparagine-803 
(HIF-1) and asparagine-851 (HIF-2) in CTAD in the presence of oxygen and modulates 
their transcriptional activity. This hydroxylation prevents the binding of co-factors 
CBP/p300 and thereby represses the transcriptional activity of HIF in normoxia. FIH 
also requires 2-oxoglutarate and iron for its activity like PHDs being member of the 
same family of dixoygenase64. FIH has a lower Km for oxygen than PHDs have, making 
the PHD respond to a lesser decrease in oxygen levels117 and  become inactive to 
stabilize HIF-1 alpha, while at the same time transcriptional activity of HIF is still be 
inhibited by FIH experiencing saturating oxygen concentrations.
Other PAS family members such as MOP3 and MOP9 interact with HIF-1 alpha to form 
active transcription heterodimers; however their targets are still elusive118-120. P14ARF 
tumor suppressor protein sequesters HIF-1alpha to nucleolus and inhibits its 
transcriptional activity121. PER2 (Period circadian protein homolog 2), a circadian factor 
prevents the transcriptional activity of HIF-1 and ARNT complex, possibly through a 
protein-protein interaction122. Contrarily, proteolytical degradation of PER1 is prevented
by interaction of HIF-Į ZLWK 3(5123. COMMD1 (COMM domain-containing 1)
protein binds to the amino terminus of HIF-1 alpha and prevents the dimerization of 
HIF-ĮZLWK+,)-ȕWKHUHE\PRGXODWLQJ+,)-1 alpha degradation as well124.
HIFĮ mRNA stability is also crucial for HIFĮ protein levels and function. HIF mRNA 
can be negatively regulated by mRNA-destabilizing protein TTP (tristetraprolin) that 
directly binds to 31UTR of HIF-1 mRNA and regulates HIF-1 alpha levels in hypoxia125.
MiR155 represses HIF-1 alpha mRNA, protein and its transcriptional response during 
hypoxia126. It is interesting to note that miR155 is induced by HIF-1 during prolonged 
hypoxia resulting in a negative feedback loop mechanism. Also miR17-92, directly 
represses HIF-1 interestingly just in normoxia but not in hypoxia126,127.
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Co-activators play a vital role in initiation of HIF-1 alpha transcriptional activity. PKM2 
enhances binding of HIF-1 alpha to HREs to promote transcription under hypoxic 
conditions. PKM2 is also induced by HIF-1 resulting in a positive feedback loop 
mechanism128. SUMO1/sentrin/SMT3 specific peptidase-3 SENP3 enhances binding of 
p300 to HIF-1 alpha and increases transcription by de-SUMOylation of p300 during 
mild oxidative stress129. Pontin, a chromatin remodeling factor is a coactivator of HIF-1
alpha by mediating the interaction of HIF-1 and p300 for initiating transcription in 
hypoxia130. A growth suppressor, Necdin, inhibits transcriptional activity of HIF-1 alpha 
during hypoxia by association with ODD domain. Moreover Necdin decreases HIF-
1alpha protein level and mediates HIF-1 degradation131. SIRT1 deacetylates lysine-674 
on HIF-1 alpha and impedes p300 recruitment and transactivation of target genes while 
p300/CBP-associated factor (PCAF) acetylates the same residue and enhances binding 
of p300 with HIF1ĮIRULQLWLDWLQJWUDQVFULSWLRQ132. It has been shown that CITED2 and 
CITED4 bind to p300/CBP preventing its interaction with HIF-1 alpha thereby 
interfering with HIF-1 alpha activity133,134. Estrogen-related receptors (ERRs) serve as 
cofactor for HIF-1 alpha during hypoxia, by direct interaction135.
Several other interacting proteins are involved in the recruitment of coactivators and 
modulate HIF transcription. For example, CTAD of HIF-1 alpha is modified by a thiol-
redox regulator Ref-1, which ultimately facilitates the binding of coactivators 136,137.
Histone deacetylase 7 (HDAC7) forms a complex with HIF-ĮDQGSXQGHUK\SR[LF
conditions and increases HIF-Į WUDQVFULSWLRQDO DFWLYLW\138. Phosphorylation of HIF-1
alpha by MAPK enhances the transcriptional activity without affecting HIF-1 alpha 
stability or DNA binding capacity139.
1.5.5 HIF function
When the oxygen levels decrease during hypoxia, PHDs activity is inhibited leading to 
the stabilization of HIF-alpha. Stabilized HIF translocates to the nucleus and dimerises 
with ARNT (HIF-1 beta)140 and  binds to HREs to promote transcription of 
approximately 100 target genes54,55,139 that participate in regulation of several processes 
such as erythropoiesis (erythropoietin), angiogenesis (vascular endothelial growth 
factor, Angiopoietin 1 and 2, E-cadherin etc), glucose and energy metabolism (glucose 
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transporter, phosphoglycerate kinase 1), cell differentiation, cell survival, apoptosis, 
tumor development etc141-144.
HIF also plays a pivotal role for development during embryogenesis. HIF-1 alpha 
knockout mice stop the development at E8.5 and eventually die at E10.5 due to vascular 
defects and abnormalities in cardiac and neural developments145-147. Like HIF-1 alpha 
knockout mice, HIF-2 alpha knockout mice have high embryonic lethality between E9.5 
and E16.5148-150. However, replacement of HIF-1 alpha in HIF-2 knock mice cannot 
rescue them from lethality151. This shows the distinct functions of HIF-1 alpha and HIF-
2 alpha despite the high level of sequence homology, at least during embryo 
development. Haploinsufficiency of HIF-2 alpha (EPAS-/-) resulted in a strain-specific 
phenotype in mouse with metabolic defects and impaired homeostasis towards reactive 
oxygen species (ROS)150. HIF-1 beta also plays a vital role in embryo development, as 
deletion of HIF-1 beta leads to death due to vascular and placental abnormalities152,153.
HIF is also involved in many other processes such as migration, proliferation, wound 
healing, ischemia, inflammation, differentiation etc. Hypoxia through HIF induces 
migration of fibroblasts and keratinocytes154,155 and induces members of the integrin 
superfamily (CD11b/CD18) that enhance the migration of leukocytes156,157.
In general the undifferentiated state of cells is maintained in hypoxia. However the 
effect is cell specific as hypoxia inhibits differentiation of preadipocytes and myoblasts 
158,159but promotes differentiation of other cell types, such as neural crust stem cells and 
mouse mammary epithelial cells160,161. Specific functions of HIF-2 alpha were also 
identified in controlling the undifferentiated state. Oct-4 which is important in 
maintaining the undifferentiated state of stem cells is controlled only by HIF-2alpha162.
HIF pathway plays an important role in regulating the inflammation response as well. 
Inactivation of the HIF-1 pathway leads to inhibition of motility, cell aggregation and 
pathogen killing capacity after phagocytosis of myeloid cells163. Hypoxia also promotes 
the secretion of inflammatory chemokines164 important to attract monocytes and 
neutrophils165. Interestingly the chemokines activate a positive feedback on HIF 
signaling mediated by ROS that stabilize HIF-1 alpha165 and by an additional effect on 
increasing the DNA binding capacity of HIF-1 alpha and consecutively expression of 
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HIF-1 target genes166. Moreover hypoxia regulates the reaction to inflammation through 
HIF independent mechanisms as well. NF-NB that has an essential role in inflammatory 
and immune responses is induced in hypoxia through a direct effect on IkkE 167.
Wound healing occurs in a relatively hypoxic milieu being generally surrounded by 
damaged vessels with impaired blood flow but having in the same time high oxygen 
need for sustaining the healing process. Hypoxia promotes the angiogenic process and 
tissue repair by induction of many target genes important for wound healing168. It has 
been shown that motility of keratinocytes was increased due to hypoxia around the 
wound, and this promotes wound healing by activating re-epithelialization and closure 
of wounds155. HSP90 alpha for instance which is induced by HIF-1 alpha stimulates 
migration of fibroblasts and healing 169.
1.6 NOTCH SYSTEM
The Notch signaling pathway contributes to the multi-cellular development by 
controlling cell fate decisions and consequently, morphogenesis.  Notch signals control 
cellular lineages by linking the fate of one cell to that of a neighboring cell, through the 
interaction of the Notch surface receptor expressed on one cell with membrane-bound 
ligands expressed on the surface of an adjacent cell. The first report on Notch described 
a novel phenotype in the fruit fly Drosophila melanogaster, characterized by a notched 
wing margin170-172. After the initial findings two decades later, in 1940 it has been shown 
that homozygosity for the notched wing allele resulted in embryonic lethality and the 
neural tissue expanded at the expense of ectoderm, establishing Notch as a controller of 
cell fate decisions from uncommitted progenitors. The research on Notch system has 
expanded enormously after the cloning of the Notch gene  establishing the role of Notch 
signaling in disease and development173.
1.6.1 A molecular overview of the Notch System
Notch signaling operates between juxtaposed cells, where membrane bound receptors 
(signaling receiving cell) and ligands (signal sending cell) need a close physical contact 
to initiate the signaling process. The Notch receptor in itself is the effector molecule of 
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the pathway and operates without need of second messengers (such as cGMP, cAMP 
etc), a common feature for other signaling pathways.
1.6.2 Notch Receptors
Notch receptors have developed during evolution from just one Notch receptor in 
Drosophila, 2 Notch receptors in C elegans to reach 4 different Notch receptors 
(Notch1-4) in most vertebrate species. The Notch receptors, Notch 1-4 (figure 4) are 
single-pass transmembrane proteins composed of 29-36 tandemly arranged EGF 
repeats174-177. The EGF repeats 11 and 12 play an important role in the interaction of the 
ligand to the receptor in order to initiate signaling178. Moreover the extracellular domain 
has three cysteine-rich family specific LNR domains (Lin Notch Region present only in 
Notch related proteins at C-terminal to EGF repeats). LNR region negatively regulates 
Lin proteins (Lin proteins facilitate the intracellular signaling) and participates in 
maintaining Notch receptors in resting state before binding to ligand. The Notch 
intracellular domain (NICD) contains RAM (RBP-Jk associated molecule) domain and 
several ankyrin repeats that are involved in interaction with other proteins such as the 
CSL complex179-181. Other intracellular domain includes a C-terminal PEST region and 
RE/AC domain182 that confers the transactivating capacity and the specificity of the 
Notch receptor by binding to RBP-Jk182,183. The PEST domain is believed to be 
important for stability and ubiquitination184,185. On both sides of the ankyrin repeats 
region NICD has two nuclear localization signals (NLSs)186,187. Notch receptors 1-3
have two NLSs, whereas Notch4 has one NLS with a small intracellular domain188.
After translation and insertion into the endoplasmic reticulum membrane, the newly 
synthesized Notch receptor interacts with O-fucosyltransferase-1(Ofut1), an enzyme 
catalyzing the addition of fucose sugar moieties to EGF repeats of Notch189,190. The 
Notch receptor is subsequently transported through the secretory pathway to the Golgi 
network for further glycosylation with importance for future interaction of the receptor 
with the ligand which is catalyzed by the fringe family of glycosyl transferases191-193.
Fringe originally identified in Drosophila has three mammalian homologs – lunatic, 
radical and manic fringe194-196
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In the trans-Golgi network Notch undergoes a proteolytic processing event (known as 
site 1 or S1 cleavage) mediated by a furin-like convertase enzyme197,198. The cleavage is 
important for maturation of the protein and for creation of a heterodimeric Notch 
receptor. Only trace amounts of non-S1 cleaved forms of Notch can be found at the cell 
surface199.
1.6.3 Notch ligands
There are at least 5 functional Notch ligands in vertebrates: three orthologs of 
Drosophila Delta (Delta or Delta-like [Dll] 1200, 3201, and 4202) (figure 4) and two of 
Drosophila Serrate (Jagged1203 and Jagged2204). All ligands are able to interact with all 
the Notch receptors and induce the second cleavage at the extracellular level205-207.
However, all ligands have different expression patterns and their specific 
deletion/inhibition results in diverse outcome208. Like Notch receptors, Notch ligands 
are also single-pass transmembrane proteins and are also composed of a large and 
variable number of EGF-like repeats in their extracellular domain but with a small 
intracellular portion. Notch ligands internalize into endosomes to achieve Notch 
activation and present themselves at the cellular membrane in the signal sending cell. 
This process is regulated by an ubiquitination assisted by E3-ubiquitin ligases 
Mindbomb and Neuralized209. This step is central in Notch signaling as deficiency in 
Mindbomb leads to defective Notch activation210,211. The N-terminal part of Notch 
ligand has a DSL (Delta and Serrate/jagged in Drosophila and vertebrates, Lag2 in 
caenorhabditis elegans) domain which is important for Notch-Ligand interaction212,213.
In contrast to Notch receptors, Notch ligands have a relatively short intracellular 
domain that contribute to endocytosis and interaction with different intracellular 
proteins 214. Also the existence of non-DSL ligands have been proposed, including 
F3/contactin (which acts as a ligand in oligodendrocyte maturation)215 and DNER 
(which acts as neuron specific Notch ligand)216. However more studies are needed to 
understand the mechanism behind this ligand-receptor interaction.
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Figure 4: Mammalian Notch Receptors and Ligands
1.6.4 Notch Activation
The key to Notch receptor activation is the regulation of ectodomain shedding. The 
interaction of Notch Ligands (signal sending cell) with Notch receptors (signal receiving 
cell) elicits two essential proteolytic cleavages (figure 5). First the binding of ligand to 
receptor induces a conformational change in LNRs present in the negative regulatory 
region of Notch receptors, which is followed by exposure of S2-site open for cleavage 
and leads the DSL sites of the ligand for endocytosis217-220. An S2 cleavage is dependent 
on ligand binding and is done by the metalloprotease ADAM called TACE (TNF- alpha 
converting enzyme)221,222 followed by an S3/S4 intramembranous cleavage in the 
hydrophobic milieu of the lipid bilayer by the large gamma-secretase enzyme 
complex223-225.
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Figure 5: Activation of the Notch signaling pathway 
Gamma-secretase cleavage releases the NICD (Notch intracellular domain) into 
cytoplasm that translocates to the nucleus226. NICD binds to CSL (named after CBF1, 
Su(H) and LAG-1), a DNA binding protein also known as RBP-Jk (recombination 
signal sequence binding protein-Jkappa) that is ubiquitously expressed (CBF1 in 
drosophila)227,228. NICD subsequently recruits its coactivators, mastermind-like proteins 
(MAML) and CBP/300 to promote transcription229-233. Turnover mechanism is 
important in controlling Notch signaling. MAML enhances phosphorylation of NICD 
and the turnover process229. NICD in the nucleus is quite unstable234. NICD 
ubiquitination takes place when MAML phosphorylates the PEST domain that leads to 
proteasomal degradation231.
1.6.5 Notch downstream target genes
Several target genes are modulated by Notch signaling. Enhancer of split complex in 
Drosophila was the first identified Notch target gene235,236. Other classical Notch target 
genes are Hes237 gene family (Hairy/Enhancer of split) and Hey238 genes which are 
closely related to Hes gene family and are direct downstream targets of Notch signaling. 
Following the activation of the Notch receptor, NICD is recruited and induce 
transcription of these genes by binding to CSL on their promoter regions237,239. To date 
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seven Hes (Hes 1-7) and three Hey (Hey 1-3) genes have been identified240. It has been 
shown that Hes1, Hes5, Hes7 and Hey gene family are Notch target genes241. Hes and 
Hey genes encode basic helix-loop-helix transcription factors of the class C type that act 
as transcriptional repressors242,243. The transcriptional repression blocks the expression 
of several genes i.e. MyoD181 in developing muscles or neurogenin244 in nervous tissue 
that are important in promoting tissue differentiation. Hes and Hey bind to co-factors 
such as E12/E47 and sequester them from binding partners such as Mash1 and MyoD 
which are important for inducing a transcriptional response181,244. In this way Hes and 
Hey acts a transcriptional repressor proteins without binding to the DNA promoter sites. 
Several other genes modulated by Notch signaling were identified through genome-wide 
transcriptome analysis, i.e CyclinD1 (coordinates mitotic events), c-Myc (cell 
proliferation and cancer), p21 (regulator of cell cycle progression), NFkB2 (regulates 
apoptosis), Snail (assists in mesoderm formation), ADAM19 (Involved in cell-matrix 
interaction, neurogenesis etc.) and Bcl-2 (apoptosis regulator protein)241,245,246. Nrarp is 
activated by a CSL-dependent Notch activation and have a blocking effect on Notch 
signaling247. Deltex1 (controls cell fate of neural progenitor cells by blocking binding 
partners such as Mash1248) is another negative regulator of Notch signaling but also a 
Notch target gene. 
1.6.6 Notch function
As mentioned before, Notch plays an essential role in embryonic development but also 
in tissue homeostasis during the adult life, by regulating cell fate decisions, proliferation, 
differentiation and apoptosis249-251. Lateral inhibition is an important Notch function, 
where the signaling restricts cell fate decisions and differentiation for example early 
differentiating cells signals to the neighboring cells to not differentiate into the same cell 
type252. Functions of Notch signaling are cell-context dependent. In consequence Notch 
promotes proliferation of leukemia cells by inducing c-Myc 253 but suppress 
proliferation of lung cancer cells via p21 and p27254. The oncogenic role of Notch was 
first described in T-cell acute lymphoblastic leukemia (T-ALL)174. Gain or loss of 
function of Notch is associated with other cancers such as skin cancers255.
Notch plays a key role in Central Nervous System (CNS). Notch signaling inhibits 
differentiation of uncommitted stem cells and stops their differentiation into neurons256-
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258. Notch receptors are also expressed in post-mitotic neurons and their activation leads 
to change in neurite morphology (decrease in neurite elongation and increase in their 
branching259,260). Notch controls also other cells types in CNS such as oligodendrocytes 
by inhibiting their maturation and differentiation into myelinating oligodendrocytes261.
Notch signaling is central in early embryogenesis by guiding the somites and giving rise 
to axial skeleton in vertebrates through Hes transcription factors262. Missense mutations 
in notch signaling are followed by defects in axial skeleton as in Dll3263 or in 
glycosyltransferase Lunatic fringe264. Muscle development is also modulated by Notch 
signaling by upregulating Hes and Hey genes, which represses MyoD which actively 
participate in promoting myogenic differentiation181.
The Notch system has a profound effect on the vascular system as well. Notch1 
deficiency leads to a phenotype with vascular malformations265. Notch1 alone or Notch1 
and 4 double knockout mice exhibit a defect in the vascular remodeling, a similar 
phenotype that was observed in Jagged1 knockout mice266. Notch4 homozygous mutants 
developed however normally and are fertile265. Recent studies pointed out the relative 
importance of Dll4 in vascular development. Even lack of a single Dll4 allele in mice 
leads to vascular defects and embryonic lethality, exactly like Notch1/Notch4 double 
knockout mice267-269. On the other hand Dll4 is overexpressed in tumor vessels 
compared to normal adjacent vascular tissues270,271. Dll4 activates Notch in neighboring 
cells and restricts endothelial sprouting and proliferation by suppressing VEGF 
receptors272,273.
Recent advances suggest a role of Notch signaling in diabetes as well. Pharmacological 
blockade of Notch VLJQDOLQJZLWKȖ-secretase inhibitors or haploinsufficiency of Notch1 
markedly increases insulin resistance via FoxO1 dependent manner274. Moreover, Notch 
signaling activation was observed in diabetic nephropathy275 with unclear specificity 
since stimulated Notch signaling is present in most of the glomerulosclerotic diseases276.
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1.7 DNA VACCINES
DNA vaccines are made from DNA sequence coding for the antigenic protein of interest 
which is inserted into a plasmid vector. Inserted DNA is then translated in the host with 
production of the antigenic protein that will elicit an immune response277,278.
DNA vaccines activate the cell-mediated immunity together with humoral immunity279-
281. DNA vaccination is safer (no risk of infection), cheaper (no need of costly 
equipment for synthesis), easier to store (can be stored in ambient temperatures) and use, 
compared with the conventional vaccination methods. Traditional vaccines can be 
potentially fatal since weakened form of an infectious organism is delivered into the 
host. They provide primarily just humoral immunity and refrigeration is needed for 
storage 282. There has been an explosion of patents applied for DNA vaccines in the last 
decade and several DNA vaccines  are already in clinical trials for different diseases like 
influenza, malaria, hepatitis, HIV and tuberculosis 277.
In 1990 it was first shown a sustained expression of a protein in the mouse quadriceps 
by injecting DNA encoding a lactase driven reporter genes283. Subsequent studies 
showed that DNA delivery (vaccination) has a high potential and can overcome the 
problems posed by protein and carbohydrate vaccines. Injection of a plasmid containing 
DNA coding for the influenza nuclear viral protein (antigen) into mouse muscle results 
in increased CD8+ cytotoxic T lymphocytes and protecting the mice from recurrent 
influenza challenges284.
DNA vaccines can be delivered either intramuscularly, intradermally or 
intraperitoneally. Several delivery techniques have been employed as electroporation 
and gene gun techniques 277. In recent years Nano particles285 were used to both protect 
DNA from degradation and to increase the phagocytic activity of APCs (antigen 
presenting cells).
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1.8 HYPERBARIC OXYGEN THERAPY
Hyperbaric oxygen therapy (HBOT) is exposure to pure oxygen (100%) at higher
pressure (>1 bar) than at the sea level. HBOT has been used for many years as a
therapeutic agent for several indications such as carbon monoxide and cyanide
poisoning286,287. HBOT has also been used as an adjuvant treatment for patients with
diabetic foot ulcers288.
HBOT activates several mechanisms with potential relevance for improving wound 
healing. HBOT improves neutrophil function and helps to combat bacterial infections 
and can be used as an alternative therapy for treating drug resistant microorganisms289-
292. HBOT has a vasoconstrictory effect having a positive effect by reducing edema 
around the wounded tissues287. HBOT stimulates the activity of osteoclasts, activates 
fibroblasts and stimulates angiogenesis with potential positive effects on wound 
healing293.
Angiogenesis (formation of new blood vessels from pre-existing vessels) and
vasculogenesis (formation of new vessels by endothelial progenitor cells) are two main
mechanisms that contribute to neovascularization. Angiogenesis is stimulated by local
factors such as VEGFA and vasculogenesis by recruitment and differentiation of
endothelial progenitor cells (EPC)294-296. Extracellular matrix (ECM) is the largest
component of skin and is composed of polysaccharides, collagen proteins etc. HBOT
enhances extracellular matrix formation, an oxygen dependent process important for
neovascularization and wound healing297-300. Stem/progenitor cells migrate to the site of
tissue injury, replace the cells lost and act as a repair system for the wound healing
process. Nitric oxide synthase 3 (NOS-3) activity is important for EPC mobilization301
and exposure to HBOT rapidly increased the EPC mobilization by increasing the NO
synthesis in humans and mice302. However EPC mobilization is impaired in diabetic
patients probably due to decreased NOS-3 activity in presence of high glucose and
insulin resistance302-304. In reperfusion studies it has been shown that leukocytes bind to
ischemic tissues, releases free radicals and proteases leading to damage of the
tissues305,306. Hyperbaric oxygen treatment reduces the adherence of leukocytes and
improves the recovering of the ischemic tissues307. Moreover HBOT has several anti-
infectious effects as it improves bactericidal action of leukocytes308, increases free
radical production and oxidation of proteins and lipids in the bacterial membrane
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inhibiting consequently the bacterial metabolic function309,310. Also, an increase in
partial oxygen pressure in the environment creates an unfavorable condition for
anaerobic bacteria311.
HBOT has potential complications although with low incidence as middle ear
barotraumas312,313. Reversible myopia is a problem normally seen due to oxygen
toxicity312. Animal studies showed development of cataract after prolonged HBOT
treatments314-316.
Several clinical trials were conducted to assess the role of HBOT in the treatment of
diabetic foot ulcers. Even though most of the studies reported positive effect some
methodological issues preclude a clear conclusion. A lot of studies were retrospective or
when they were performed prospectively they were non-blinded or unclear randomized
317. However a recent monocentric, double blinded and clearly randomized study points
out on improved wound healing and improved quality of life after one year 313, 318. Even
though the other prospective studies with enough quality to be taken in consideration
suggest a superior effect of HBOT on diabetic wounds they show absence of variation in
the control group (no healing) 319,320 that contribute to a high heterogeneity (I=85%) that 
preclude observation of a positive effect after one year 321. It is therefore a big need for 
additional clearly defined studies with more participants that could define the exact 
subgroup of patients that will benefit most from the HBOT. 
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2 AIMS
The overall aim of the work presented in this thesis was to investigate specific
pathogenic mechanisms that contribute to the defective wound healing in diabetes in
order to suggest potential new therapeutic targets.
Specific aims
x To identify intracellular pathways modulated by high glucose levels with
potential relevance for wound healing processes.
x To study the mechanisms by which glucose contributes to HIF and Notch
modulation
x To study the potential therapeutic effect of HIF and Notch modulation for
diabetic wound healing
x To study the effect of HBOT on HIF signaling and the therapeutic relevance for
diabetic wound healing.
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3. MATERIALS AND METHODS
Animals: C57BL/KsJm/Leptdb(db/db) diabetic mice and their heterozygotes control 
non-diabetic littermates (age 14-20 weeks) were originated from breeding pairs obtained 
from Charles River (Belgium) (Paper I, II, IV). Db/db mice represent a commonly used 
model to study type 2 diabetes complications. Due to a deficient leptin signaling, these 
mice become hyperphagic with subsequent obesity, hyperglycemia and dyslipidemia 
after 8 – 10 weeks of age322.
Skin specific Notch 1 knockout mice (Paper II) were generated from crossing  
N1flox/N1flox females KRT14-Cre males (Breeding pairs obtained from Charles River, 
Belgium), and in F1, N1flox/+; KRT14-Cre/+ male offsprings were backcrossed to
unrelated N1flox/N1flox females. The F2 N1flox/flox; KRT14Cre+/+ mice displayed 
typical hair phenotypes (without hair) but not all the other offsprings (N1flox/+;
KRT14-Cre/+, N1flox/N1flox or N1flox/+). Heterozygous N1flox/+ were used as
controls. Female BALB/C mice, 6 to 8 weeks old were used for Dll4 vaccination 
experiments (Paper III). All animals were maintained under controlled light and 
temperature, with free access to standard food and water. The experimental procedure 
for animals was approved by the North Stockholm Ethical Committee for care and use 
of laboratory animals.
Streptozotocin Induced Diabetes: Diabetes was induced in N1flox/flox;
KRT14Cre+/+ mice and Heterozygous N1flox/+ by streptozotocin (STZ) according to the 
instructions from AMDCC (Animal Models of Diabetic Complications Consortium). 
Briefly, the animals (8-10 weeks) received 50mg/kg STZ mixed in sodium citrate buffer 
(i.p) daily for five consecutive days. All the treated mice became diabetic after 2 weeks 
from the first STZ injection. Animals were kept diabetic for three weeks before the start 
of wound healing experiment (13-14 weeks).
Wound Model:  Following blood glucose control, general anesthesia was performed 
with 3% isoflurane (Abbott). The hair of the back was shaved with an electric clipper 
followed by a depilatory cream. The skin was rinsed with alcohol and two full-
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thickness wounds extending through the panniculus carnosus were made on the 
dorsum on each side of midline, using a 6-mm biopsy punch. A transparent dressing 
(Tegaderm; 3M) was applied to cover the wounds after topical application of drugs: 
Paper I: ȝORI'02*P0');P0RUYHKLFOHDORQH3DSHU,,9IRXU
LQMHFWLRQVRIȝORIWKHYLUDOVXVSHQVLRQ9 pfu/ml) containing HIF-1 V-N, HIF-1
V-NC, or LacZ-expressing adenoviruses were injected intradermally into the wound 
edges using a 30-gaXJHQHHGOH3DSHU,,ȝORI'$37ȝ0/-685, 458 (100 
ȝ0RU'062FRQWURO DQG LQ67=LQGXFHGGLDEHWLF1RWFKNQRFNRXWV)ROORZLQJ
the surgical procedure, the animals were individually housed. During the first 2 days, 
the animals received s.c. buprenorphine (0.03 mg/kg) twice a day for relief of any 
possible distress caused by the procedure. In the experiments aimed to analyze 
histology, mRNA, or protein expression, the wounds were harvested at 7 days after 
VXUJHU\ § FORVHG )UHVKO\ PDGH WUHDtment was applied through the dressing 
using a 30-gauge needle every other day. Viruses (HIF-VN, HIF-V-NC, LacZ) were 
inoculated once at the beginning of the experiment, all the other treatments every 
other day. Each treatment was evaluated in 10 animals per group.
Wound Analysis: Digital photographs were recorded at the day of surgery and every 
other day after wounding. A circular reference was placed alongside to permit 
correction for the distance between the camera and the animals. The wound area was 
calculated in pixels with ImageJ 1.32 software (National Institutes of Health), 
corrected for the area of the reference circle and expressed as percentage of the 
original area.
Tissue Preparation and Histological Analysis:  After fixation in formalin, the 
sDPSOHVZHUHHPEHGGHGLQSDUDIILQDQGVHFWLRQHGȝP)RUKLVWRORJLFDOHYDOXDWLRQ
sections were deparaffinized and rehydrated followed by hematoxylin and eosin 
staining. All slides were then evaluated by light microscopy by two independent 
observers unaware of the identity of the biopsy, using a semi-quantitative score to 
evaluate vascularity, granulation, and dermal and epidermal regeneration as 
previously described323 and internally validated in our laboratory. We used four-point 
scales to evaluate vascularity (1, severely altered angiogenesis with one or two 
vessels per site and endothelial edema, thrombosis, and/or hemorrhage; 2, moderately 
altered angiogenesis with three to four vessels per site, moderate edema and 
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hemorrhage, but absence of thrombosis; 3, mildly altered angiogenesis with five to 
six vessels per site, moderate edema, but absence of thrombosis and hemorrhage; and 
4, normal angiogenesis with more than seven vessels per site with only mild edema 
but absence of thrombosis and hemorrhage) and granulation tissue formation (1, thin 
granulation layer; 2, moderate granulation layer; 3, thick granulation layer; and 4, 
very thick granulation layer) and a three-point scale to evaluate dermal and epidermal 
regeneration (1, little regeneration; 2, moderate regeneration; and 3, complete 
regeneration).
Immunohistochemistry staining and Evaluation: We evaluated microvessel density by 
semi-quantitative, double-blind analysis of the specific binding of GS-1 isolectin B4 to 
microvascular structures using a four-point scale (0, no positive vessels; 1, low number 
of positive vessels; 2, moderate number of positive vessels; and 3, high number of 
positive vessels). Isolectin B4 binding was performed using biotinylated isolectin B4 
(diluted 1:25). Expression of the adenovirus-PHGLDWHG WUDQVIHU RI ȕ-galactosidase was 
evaluated by immunohistochemistry using anti-ȕ-galactosidase antibody (1:500) from 
Abcam. Matched IgG isotype controls were included for each marker. In paper I, the 
hypoxia level within the wounds was evaluated using the Hypoxiprobe kit (Natural-
Amersham Pharmacia) following the instructions of the manufacturer.
Cell Culture: Primary Human Dermal fibroblasts (HDFs) (Promocell, Germany),
Mouse embryonic fibroblasts (MEFs) (kindly offered by Dr. Daiana Vasilcanu, Cancer 
Centrum Karolinska), Primary mouse skin fibroblast cultures (prepared as described in 
the next section) - HDFs, MEFs and 3T3 cells were cultured in DMEM (5.5 mM 
glucose) supplemented with 2mM L-glutamine, 100 IU/ml penicillin and 
streptomycin, and 10% heat-inactivated FBS (Invitrogen). Human Dermal 
Microvascular endothelial cells (HDMECs) purchased from Promocell, were cultured 
in the ready to use medium provided by Promocell. All the cells were maintained in a 
humidified atmosphere with 5% CO2 at 37 °C in a cell culture incubator. Only cells 
between passages 4 to 9 were used.  The human SKRC-7 cell line, originating from 
renal carcinoma from a patient with point mutated VHL, was kindly provided by E. 
Oosterwijk (Nijmegen, The Netherlands) and maintained as described324 .
Establishing fibroblast primary cell culture: Primary mouse skin fibroblasts were 
established by skin explant technique325. The cells were maintained in a humidified 
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atmosphere with 5% CO2 at 37 °C DMEM (5.5 mM glucose) supplemented with 2 
mM L-glutamine, 100 IU/ml penicillin and streptomycin, and 10% heat-inactivated 
FBS. Only cells between passages 4 and 9 were used (Paper I). 
Hypoxia treatment: Cells were incubated in a Modular Chamber (Billups-Rothenberg) 
which is flushed with a gas mixture (95% N2 and 5% CO2) until the oxygen 
concentrations lowered to 1%, oxygen levels were constantly measured and monitored 
by an oxygen meter (Dräger) (Paper I).
Activation of Notch signaling using Recombinant ligands: Cell culture plates were 
first coated overnight with Protein G (Invitrogen) 50 mg/ml in PBS at room temperature 
(RT) and then washed two times with PBS and blocked with 3% BSA in PBS for 2 h at 
RT. Plates were washed again two times with PBS and incubated with either 
recombinant Jagged1-)&FKLPHUDȝJPO&W1R– 599-JG from R&D systems) or 
Dll4-&)ȝJPO(Ct.No-1389-D4/CF) for 2–4 h at RT. After washing two times with 
PBS, cells (MEFs and HDFs) were immediately plated and then grown in DMEM 
containing either 5.5mM or 30mM glucose (Paper II).
Reporter Gene Assay: In Paper I, 3T3 cells were transfected with 500 ng of a GAL4-
driven luciferase reporter gene plasmid and 10 ng of NTAD residues (pFLAG-GAL4-
P+,)Į-[531–584]) or CTAD residues (pFLAG-GAL4-P+,)Į-[772–822]) using 
Lipofectamine 2000 (Invitrogen) in 60-mm plates, following the instructions of the 
manufacturer. In Paper II, HDFs placed on Jaggged1 coated plates were transfected with 
500 ng of 12XCSL luciferase reporter gene plasmid (kindly offered by Dr. Teresa 
Pereira, CMB) using Lipofectamine 2000 (Invitrogen) in 100-mm plates, following the 
instructions of the manufacturer. In Paper IV, Transcriptional activity of HIF-ĮZDV
assayed using a plasmid (pT81/HRE-luc) containing hypoxia responsive element (HRE) 
from erythropoietin. HDFs were co-transfected in 12 wells plates with 500ngs of HRE 
plasmid and 25ngs of Renilla plasmid (used for normalization) (Promega) using 
Lipofectamine 2000 in Optimem (Life Technologies) for 3h, when the medium was 
changed to regular cell culture medium (DMEM with 10% FBS). After exposure to the 
planned experimental conditions, the luciferase activity was assayed (BioThema) in the 
cell extract and expressed relative to the total protein concentration as evaluated by 
Bradford method (Bio-Rad) (as described in the Paper I, II accordingly)or relative to 
Renilla activity  (as described in the Paper IV).
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RNA interference experiments: In Paper I, Human dermal fibroblasts were 
transiently transfected with 200 pmol per well of either pVHL-siRNA (Hs_VHL_5 HP 
validated siRNA SI02664550 for gene pVHL) or scrambled siRNA from Qiagen using 
HiPerFect. transfection reagent (Qiagen). After 48 h, cells were exposed to different 
glucose concentrations (5.5 mM and 30 mM) for another 48 h when the RNA was 
prepared as described. In Paper II, siRNA oligos against Notch 1,3 and 4 were 
obtained from Sigma (SASI_Mm01_00104901 N1, SASI_Mm01_00057178 N3, 
SASI_Hs01_00052678 N4). All stars negative control (scrambled) siRNA from 
Ambion was used as a scrambled siRNA control. All siRNAs were reconstituted under 
RNase-free conditions according to the manufacturer’s protocol, using the buffers 
supplied. HDFs or HDMECs were transfected with the 20nM siRNAs at a confluence 
of 80–90% with HiPerFect Transfection Reagent (Qiagen) in OPTIMEM-1 medium 
(GIBCO) according to the supplier’s protocol. Transfected cells were trypsinised and 
used for either migration assay or angiogenesis assay 
In vitro Migration assay: The cell migration was studied using the “in vitro scratch” 
assay as described326. Briefly, HDFs were plated in 12 wells cell culture plates that were 
pre-FRDWHGZLWK FROODJHQ ȝJPO DQGEORFNHGZLWK%6$ %6$ LQ3%6$IWHU
reaching confluence, the cells were serum starved (overnight) and a scratch was 
performed with a micropipette tip on the following day in each well. After rinsing with 
PBS the HDFs were incubated for additional 16 hours with a gamma secretase inhibitor
 ȝ0 '$37 RU  ȝ0 /-685,458) or with control (DMSO) dissolved in DMEM 
supplemented with 0.2% FBS with different glucose concentrations (5.5mM or 30mM). 
MitomycLQ&ȝJPOZDVLQFOXGHGLQWKHPHGLDWRSUHYHQWFHOOSUROLIHUDWLRQ3LFWXUHV
were taken immediately after scratching (basal level) and after 16 hours with a digital 
camera coupled to an inverted phase microscope. The relative migration of the cells was
calculated from the area measured 16 hours after scratching relative to the basal area 
expressed in pixels, using ImageJ 1.32 (N.I.H., USA) software. The results were 
expressed as percentage from the migration of the cells grown in 5.5mM and exposed to 
control (Paper II).
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In vitro Angiogenesis Assay: HDMECs were seeded at a density of 1 × 104 cells/well in 
 ȝO FXOWXUH PHGLXP LQ D -wells plate pre-FRDWHG ZLWK  ȝO (&-Matrigel/well 
(Chemicon; Cat. No. ECM625). The tube formation was quantified 12h after the 
treatments (DMSO, DAPT, VEGFA or siRNA specific to Notch 1 and 4) by counting 
the number of sprouting tube-like structures at randomly 5 selected fields under an 
inverted phase contrast microscope at 40 × magnifications. Three independent 
experiments were performed, and the data was presented as the total number of tubes 
formed in each experiment (Paper II).
Hyperbaric oxygen treatment:
For the in vitro experiments the cells were exposed to HBO (100% oxygen at 2.5bar 
absolute pressure) for 1hr in a hyperbaric oxygen chamber while the cells used for 
control were simultaneously placed outside the chamber. For the in vivo experiments the 
animals were placed in an animal hyperbaric oxygen chamber (RSI-B11; Reimers 
Systems) and exposed to HBO at 2 bar abs for 90-min. The untreated control mice, were 
placed outside the hyperbaric chamber in the same room. HBOT session for in vivo 
experiments begins with a progressive increase in pressure for 15min, followed by 
60min of continuous exposure to 100% oxygen at 2 bar absolute. After 60min of 
exposure the pressure in the chamber is slowly reduced during a 15min period. After the 
procedure the animals were placed in single cages in the animal care room.
3H-thymidine incorporation assay: MEFs HIF+/+ and MEFs HIF-/- cells were plated at 
a density of 2 x 104 cells/well in a 6 wells plate. Cells were starved overnight and then 
exposed for two successive exposures to HBO for 60min (as described in hyperbaric 
R[\JHQ WUHDWPHQW$IWHUK IURPWKH ODVW+%2H[SRVXUHȝ&LPORI 3H-thymidine 
(PerkinElmer, Boston, MA, USA) was added to each well. Four hours later the cells 
were washed twice with cold PBS and then with cold 5% TCA followed by 
solubilization with 0.5 N NaOH. The solubilized cells (400 Pl) were mixed with 4 ml 
scintillation liquid and counted in a beta counter (Packard BioScience, Downers Grove, 
IL, USA).
Western Blotting: Western Blot analysis was performed for evaluating HIF (Paper I &
IV), Notch 1 intracellular domain (Paper II) and expression of plasmid vaccine protein 
(Paper IV). Proteins from cells or skin (extracted using 2-mm Zirconia beads and a mini-
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bead beater (Biospec Products)) were extracted using RIPA Buffer in the presence of 
protease inhibitors as described168. The same amount of protein was loaded in SDS gels 
(7%), separated by electrophoresis and transferred to a nitrocellulose membrane (Bio-
Rad). The membranes were blocked in 5% milk and further incubated first with the 
primary antibody for 3hrs in 0.1% Tween PBS, and then incubated with HRP 
conjugated anti-goat secondary antibody (Thermo Scientific, 1:3000). After extensive 
washing with PBS the complexes were visualized using enhanced chemiluminescence 
(GE Health Care) according to the manufacturer’s instructions.
Quantitative Real time – PCR: Total RNA was isolated from cells using RNeasy RNA 
extraction kit (Qiagen), and from skin using an RNeasy Fibrous Tissue Mini Kit 
(Qiagen). cDNA was obtained by reverse-transcribing total RNA with SuperScript III 
and first-strand synthesis Supermix for quantitative RT-PCR according to the 
manufacturer's recommended protocol (Invitrogen). The primers (as described in papers 
I, II, IV) designed by using the Primer 3 program (http://frodo.wi.mit.edu) or choosen 
from Harvard primer bank (http://pga.mgh.harvard.edu/primerbank/). Real-time PCR 
was performed in an Applied Biosystems 7300 or 7900 units using Platinum SYBR 
Green quantitative PCR Supermix-UDG with ROX reference dye (Invitrogen). After 
incubation for 2 min at 50 °C and 2 min at 95 °C, a two-step cycling protocol (15 s at 94 
°C, 30 s at 60 °C) was used for 40 cycles. The melting curve analysis was done using the 
program supplied by Applied Biosystems. The quality of the quantitative PCR run was 
determined by standard curves and melting curve analysis. The amplification products 
were verified by sequencing.
Statistical analysis: Differences between groups were computed using one-way analysis 
or two way repeated measures of variance (ANOVA) as appropriate, with Bonfferoni
post hoc test. A p<0.05 was considered statistically significant.
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4 RESULTS AND DISCUSSION
Diabetic foot ulcer represents a major complication of diabetes that may lead to 
amputation. For the moment, there is no specific therapy available for diabetic foot 
ulcers and it has become a priority to develop novel rational therapeutic strategies based 
on new pathophysiological mechanisms. Our focus was therefore to delineate relevant 
pathogenic pathways specifically deregulated in diabetes that could contribute to the 
defective wound healing.
4.1 High glucose modulates cellular pathways with potential relevance 
for wound healing
(Paper I and Paper II)
The central pathogenic factor for development of complications in diabetes is high
glucose concentration. During the last decade hypoxia has also started to be recognized
as an important pathogenic contributor to chronic complications of diabetes. Major
findings in the present thesis consist of the description of two new cellular pathways
with high relevance for wound healing that are specifically modulated by hyperglycemia
and contribute to defective wound healing in diabetes i.e. repression of HIF-alpha
pathway in hypoxia (Paper I) and induction of Notch Signaling (Paper II).
We first focused on the modulation of HIF-1 alpha in two cell types, essentially affected
during development of chronic complications of diabetes i.e. primary human dermal
fibroblasts (HDFs) and human dermal microvascular endothelial cells (HDMECs). In
normoxia, we could not detect any influence of high glucose concentrations on HIF-1
alpha expression. However, the hypoxia-stabilized HIF-1 alpha is impaired by glucose
as previously described by our group and others327-330 . The repressive effects of high
glucose on HIF-1 alpha stabilization were described in other primary cells and tissues
also but are different in transformed tumor cells pointing out on its specificity for
diabetes (data not shown).
High glucose destabilizes HIF-1 alpha as early as after 6hrs which highlights the
potential relevance for the immediate cell reaction to hypoxia in acute ischemic events
(acute myocardial infarction, stroke). The HIF repression induced by hyperglycemia
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continues even at later time points with potential significance for chronic complications
of diabetes since most of the tissues prone to develop complications share a hypoxic
environment (kidney, nerves, retina etc.).
In order to further understand the intimal mechanism behind the effect of hyperglycemia
on HIF-1 alpha stability we investigated the potential involvement of pVHL dependent
degradation mechanism, we could appreciate that hyperglycemia contributes to HIF-
1alpha degradation through a pVHL-dependent mechanism since HIF-1 is no longer 
modulated by hyperglycemia in renal carcinoma cells that lack functional pVHL and 
traditional target genes as VEGFA are no longer modulated in HDF if VHL is 
specifically silenced. However, VHL expression is not induced by hyperglycemia 
suggesting that hyperglycemia just increases the sensitivity of HIF-Į WR 9+/
dependent degradation. The same VHL dependent degradation modulated by glucose 
was also observed in myotubules but not in tumoral cells329.
In concordance with the VHL mediated degradation of HIF-1alpha in hyperglycemia 
PHD inhibitors are able to reverse the repressive effect of glucose. The negative 
regulatory effect of glucose was not only restricted to the stability of HIF-1alpha but 
also affected both HIF-1 alpha transactivation domains NTAD and the CTAD. In 
agreement with our results, it has been shown that hyperglycemia induced decrease in 
transactivation of HIF-1 alpha and limited the HIF-1 alpha function331. The repressive 
effect of hyperglycemia on both HIF-1alpha stability and transactivation was mirrored 
by down-regulation of several HIF-ĮWDUJHWJHQes essential for wound healing such as 
heat shock protein 90 (HSP-90), VEGF-A, VEGF-R1, stromal cell-derived factor 
(SDF)-ĮDQGVWURPDOFHOOIDFWRU6&)
The Notch signaling pathway is involved in many cellular processes with potential 
relevance for wound healing as cell differentiation, cell migration, proliferation, 
angiogenesis etc245,249,332,333. In Paper II, we have observed activation of Notch 
signaling in skin of different diabetic animals, as assessed by relative mRNA expression 
of several Notch target genes. We have therefore investigated if high glucose has direct 
effect on Notch signaling in HDFs and HDMCEs. Exposure to high glucose 
concentrations induces indeed the active intracellular domain (NICD) which is followed 
by Notch mediated transcriptional activation as shown by induction of the highly Notch 
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specific 12XCSL-luc reporter assay. Hyperglycemia induces the Notch signaling at a 
level before the cleavage of Notch receptor since treatment of the mouse embryonic 
fibroblasts (MEFs) with gamma-secretase inhibitor (DAPT) cancel the stimulatory 
effect of high glucose concentration on Hey1. Moreover the stimulatory effect of 
hyperglycemia on Notch signaling is not restricted to the fibroblasts but affects also 
other cells with important roles in wound healing e.g. human dermal microvascular 
endothelial cells (HDMEC) where several Notch-related genes (Notch1, Notch4, Hes1)
were induced by exposure to high glucose concentrations. The level of glucose inducing 
effect on Notch signaling is common in different tissues since J-secretase inhibitors are 
able to cancel the effect of hyperglycemia on functional assay performed both in HDF 
(migration assay) and in HDMEC (in vitro angiogenesis). Modulatory effects of 
hyperglycemia on Notch signaling were found as well in podocytes  276 and in neural 
stem cells334.
4.2  Glucose affects HIF-1 alpha function by different mechanisms
High glucose modulates HIF-1 stability and function at multiple levels. The effect is 
however restricted to posttranslational level (figure 6) since HIF-1 alpha RNA were not 
influenced by High glucose concentrations in either hypoxia or normoxia.
                     
Hyperglycemia modulates HIF-1 alpha degradation since it has been shown that the 
effect of high glucose on HIF-1alpha stability is cancelled if the cells were exposed to 
the proteosomal inhibitor, MG132 327. Moreover we could establish that the effect of 
glucose is mediated by a pVHL dependent mechanism. It is however an increase of the 
interaction between VHL and HIF-1alpha which is activated by hyperglycemia since 
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VHL levels are not modulated by glucose. In concordance with the central importance of 
prolyl hydroxylation for facilitating the interaction between HIF-1alpha and VHL 
prolylhydroxylases (PHD) inhibitors (DMOG and DFX) are able to rescue at least 
partially the effect of hyperglycemia on HIF-1 alpha stability and function both in 
normoxia and in hypoxia. However, it should be stressed that HIF-1 alpha 
destabilization in high glucose is only partially reversed by the PHD inhibitors 
suggesting the role of other mechanisms, in addition to proline hydroxylation, as already 
suggested before327.
Methylglyoxal is a reactiveDoxoaldehyde produced in the cells exposed for long time 
to hyperglycemia that was reported to modulate HIF-1 reaction to hypoxia. 
Methylglyoxal modifies HIF-ĮDW WZR VSHFLILF UHVLGXHV DUJLQLQHDQGDUJLQLQH
and reduces its interaction with HIF-1 beta. 335. Moreover methylglyoxal affects p300 
interaction with HIF-ĮDQGLQWHUIHUHVZLWK+,)-1 transactivation. An important role was 
identified in one residue in p300 since mutation of arginine 354 of p300 restored its 
interaction with HIF-Į LQ SUHVHQFH RI KLJK-glucose331. Methylglyoxal increases HIF-
1alpha degradation by increasing its interaction with molecular chaperones CHIP,
HSP40 and HSP70 which eventually leads to polyubiquitination of HIF-Į DQG LWV
degradation336. Methylglyoxal leads to accumulation of CHIP, Hsp40 and decreases the 
levels of the molecular chaperone Hsp90. It is however a more complicated interaction 
in the presence of hyperglycemia since CHIP and HSP 70 contribute to HIF-1alpha 
degradation but not HIF-2alpha degradation 337 which is in discordance with our 
observation that hyperglycemia destabilizes HIF-2alpha to the same extent as HIF-
1alpha. Interestingly, Methylglyoxal decreases Hsp90338and can modulate HIF-1alpha 
stability by this way since Hsp90 has an established role for stabilization of HIF-1
alpha108,339.
Several other factors could play a significant role in the destabilization of HIF in 
presence of high glucose. For example, p53 is able to interfere with HIF-1 alpha stability 
and activity by a pVHL independent mechanism340 and it is induced by high glucose341.,
However HIF-1 alpha is still destabilized by high glucose in fibroblasts deficient of 
p53327. Sumolyation is an important process in HIF-1 alpha stability, RSUME an 
inducer of SUMOylation increase SUMO conjugation with HIF-1 alpha and stabilize 
HIF-1 alpha115 during hypoxia. Sirtuins regulates protein functions by sumolyation and 
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SIRT1 sumolyation regulates activity of HIF-1 alpha and participates in HIF-1 alpha 
accumulation and transcriptional activity under hypoxia342. High glucose reduces SIRT1 
expression levels and enzyme activity343 making SIRT1 a potential mediator of 
hyperglycemia on HIF-1 alpha destabilization in diabetes.
By investigating mediators of hyperglycemia on HIF function we will be able to identify 
new specific therapeutic targets to rescue the repressed reaction of the cells to hypoxia 
characteristic in diabetes. 
4.3  HIF-1 alpha stabilization improves the defective wound healing in diabetes 
(Paper I & IV)
To assess the in vivo significance of the modulation of HIF by hyperglycemia we have 
further studied the modulation of HIF-1 in experimental diabetic wounds. 
In perfect agreement with the in vitro results, a general repression of HIF-1 signaling 
was recorded in wounds in diabetic mice (db/db) despite profound hypoxia as evaluated 
by pimonidazol staining. We observed both lower levels of HIF-1 alpha expression and 
lower levels of HIF target genes with relevance for wound healing (Paper I). These data 
are in agreement with previous reports in patients with diabetic chronic foot ulcers that 
express lower levels of HIF-1alpha compared with patients with chronic venous ulcers 
despite the same levels of hypoxia 327. The same destabilization of HIF-1alpha in 
diabetic skin was also reported by others344. Moreover, the fibroblasts isolated from the 
skin of diabetic patients are unable to induce VEGFA in response to hypoxia exactly 
like fibroblasts from diabetic mice331. We also observed the same inappropriate HIF 
reaction to hypoxia in diabetic kidneys345.
Low oxygen levels as a consequence of macro- and micro- angiopathy are present 
locally in patients with diabetic foot ulcers or diabetic neuropathy346-349. Based on our in 
vitro and in vivo observations on the repression of HIF-1 signaling by hyperglycemia we 
hypothesized that in diabetes the defect of the cells to adapt to hypoxia might play a 
central role in development of chronic complications. To test this hypothesis we choose 
to study the therapeutic potential of HIF-1 alpha induction for wound healing in db/db 
mice (Paper I) that are the best rodent model for wound healing defects in diabetes350.
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For inducing HIF-1 in the wounds we have used either compounds that interfere with 
activity of HIF hydroxylases, by chelating Fe2+ (DFX) or by competing with 2-
oxoglutarate (DMOG) (Paper I) or by hyperbaric oxygen therapy (HBOT) (Paper IV).
All the above treatments were able to induce HIF-1 alpha accumulation, and expression 
of HIF target genes essential for wound healing (HSP-90, VEGF-A, VEGFR1, SDF-1, 
and SCF).
Local application of HIF hydroxylase inhibitors (DMOG and DFX) or treatment with 
HBO improved the healing process in db/db mice despite the presence of persistent 
chronic hyperglycemia (Paper I and IV). However to obtain direct evidence of HIF-1
role in the diabetic wound healing, we performed a gain of function studies with 
adenoviruses expressing stable forms of HIF-1 alpha (V-N and V-NC) in which both the 
critical proline residues have been substituted with alanine’s. Indeed local injection of 
adenoviruses containing stable HIF-1 alpha around the wound edges improves the 
wound healing rate in db/db mice confirming the central role of HIF-1 repression as 
pathogenic defect in diabetic wounds. The positive effect of local HIF induction for 
wound healing in diabetes was shown in other experimental designs as well using either 
chemicals or virus mediated transfer 331,344.  The functional consequence of HIF 
hydroxylases on diabetic wounds improved several processes important for healing (i.e., 
granulation, vascularization, epidermal regeneration, and recruitment of endothelial 
precursors).
4.4 Diabetes Impairs of HIF-1 alpha regulation in several tissues
There is a large body of evidence supporting that HIF-1Į is destabilized by high 
glucose concentrations. Moreover inappropriate low levels of HIF-1 are found in 
diabetes in several tissues with negative consequences. Biopsies from patients with 
diabetic foot ulcers showed decreased HIF-1 alpha levels compared to patients with 
venous ulcers that share the same hypoxic environment but are not exposed to 
hyperglycemia327. The functional relevance of this observation was confirmed by other 
groups beside us that have also shown that gene-based therapy with HIF-1alpha 
induced acceleration of wound healing and angiogenesis in diabetic mice330,344.
Diabetes impairs through HIF-1 hypoxia-induced production of SDF-1, CXCR4, 
VEGF and eNOS and lead to endothelial dysfunction. Hyperglycemia represses HIF-1
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alpha and is followed by an increase in the myocardial infarct size in rats351. The same 
dysfunction of HIF-1 in presence of hyperglycemia is followed by decreased 
angiogenesis in diabetic patients352,353. However overexpression of HIF-1 normalized 
VEGF levels and improved myocardial capillary network following myocardial injury 
in diabetic mice354 .
In addition, increased expression or stabilization of HIF-1Į is critical to increase limb 
perfusion and function in diabetic mice, along with an increase in the number of 
circulating EPCs and vessel density355. A polymorphism of HIF-1alpha (P582S) that 
confers relative resistant to the repressive effect of hyperglycemia is associated with 
protection against nephropathy in patients with type2 diabetes345,356,357
HIF is suggested to play an important role for the function of beta cells in diabetes as 
well. Several opposing data concerning the effect of the manipulation of the HIF-1
system in beta cells are available358,359,360,361.362 suggesting that both excessive and 
inappropriate HIF-1alpha is deleterious for insulin secretion362. A polymorphism in 
HIF-1alpha was associated with type 2 diabetes345,356,357.
4.5 Blocking overactive Notch signaling improves wound healing in diabetes 
(Paper II & III)
Overactive Notch signaling in vivo confirmed our in vitro data. Notch signaling is 
overactive in the skin of different model of diabetes both in mice and in rat as reflected 
by induction of several Notch target genes (Paper II). Using a specific antibody against 
the active Notch 1 intracellular domain we could confirm an intense expression of NICD 
in the granulation tissue of the diabetic wounds (Figure 7).
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To unravel the pathophysiological role of overactive Notch for the diabetic wound 
healing, we have blocked Notch signaling using gamma secretase inhibitors (DAPT and 
L-864, 548) in experimental wounds performed in db/db mice. Both compounds 
improved significantly the wound healing process highlighting the pathogenic role of 
glucose-stimulated Notch signaling (Paper II). Moreover, the positive effects of 
blockage of the Notch signaling on wound healing seem to be specific for diabetes. We 
could not observe any effect of the gamma secretase inhibitors (Paper II) or Dll4 DNA 
vaccine (Paper IV) on wound healing rate in non-diabetic mice that confirms previous 
observations363,364. Discordant effects were observed in other wound healing models as 
corneal epithelial wound healing365 366 that might be a consequence of effectivity of the 
manipulation of the Notch signaling367.
Blocking the overactive Notch signaling in wounds increased the angiogenesis as 
assessed by isolectin staining and markers of tip cell formation and angiogenic sprouts 
as assessed by relative expression of vascular endothelial growth factor receptor 2 
(VEGFR-2), Platelet derived growth factor B (PDGF-B)368 and vascular endothelial 
growth factor receptor 3 (VEGFR-3)369 (Paper II). Moreover, treatment with DAPT is 
followed by an increase in the expression of chemokines with essential roles in the 
recruitment of endothelial precursor cells as SDF-1370 and SCF371. Taken together 
gamma secretase inhibition in diabetic wounds improves the diabetes-dependent 
repression of granulation and angiogenesis at multiple levels.
These effects were indeed confirmed in vitro by blockage of Notch signaling in HDF or 
in keratinocytes (figure 8) by exposure to gamma secretase inhibitors (DAPT and L-
685,458) rescued the inhibitory effect of hyperglycemia on cellular migration. 
Moreover, the same treatment increased the in vitro angiogenesis in HDMECs. 
However, the positive effects of Notch inhibition on migration and angiogenesis are 
mediated exclusively through Notch1 receptor, since Notch1 specific siRNA but not 
Notch3, Notch2 or Notch4 siRNA mimics the effects of gamma-secretase inhibitors 
(Paper II).
To investigate the role of Notch1 receptor in diabetes repressed wound healing in vivo,
we studied the wound healing rate in skin specific Notch1 knockout mice in which 
diabetes was induced by streptozotocin. Diabetic skin specific Notch1 knockout mice 
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have a significantly improved healing rate compared to its diabetic heterozygote control 
(Paper II) pointing out the importance of Notch 1 receptor in diabetes and its essential 
role in diabetic wound healing (figure 9). 
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4.6 Hyperglycemia induced Notch signaling mechanisms
We here report for the first time that Notch signaling is activated in diabetic skin and 
this effect is dependent on hyperglycemia. The mechanism behind the activation of 
Notch signaling in diabetes is still unclear. We have however investigated some 
potential mechanisms such as fringe and FoxO genes. Fringes (Manic, Lunatic and 
Radical fringes) are regulators of Notch signaling, by mediating O-fucosylation and O-
glycosylation372,373 of EGF repeats on Notch receptors. These posttranslational 
modifications modify the specificity of the interaction between receptors to ligands, and 
modulate Notch activity in a number of tissue specific contexts191,192,374.  For example, 
lunatic fringe (Lfng) inhibits the Notch1 and Jagged1 binding and potentiates Delta1 
signaling through Notch1, but potentiates both Delta1 and Jagged1 mediated signaling 
through Notch2375. Loss of Lfng enhances angiogenic sprouting by decreasing the 
affinity of Notch1 and Dll4 binding; in the same time, jagged1 competes with Dll4 in 
binding to Notch and thereby locally enhances angiogenic growth while Mfng 
glycosylation of Notch further increases the Dll4-Notch signaling376. Interestingly we 
have observed increase in expression of the fringes and Dll4 genes in the skin of diabetic 
animals (Paper II) that was reproduced by hyperglycemia in vitro (data not shown). 
Moreover blocking fringes by siRNA treatment in HDMECs reversed the effect of 
hyperglycemia induced Notch signaling however without been able to identify a specific 
effect on any of the isolated fringes (figure 10).


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FOX (Forkhead box) proteins plays important roles in regulating the expression of 
genes involved in cell growth, proliferation, differentiation, and longevity377. FoxO1 and 
Notch interact physically and functionally leading to activation of Notch target genes to 
regulate the progenitor cell maintenance and differentiation378. Recent evidence suggest 
a synergistic role of FoxO1 and Notch1 on insulin sensitivity. Treatment with gamma-
secretase inhibitors improves insulin sensitivity in a FoxO1 dependent manner274. This 
stimulated us to study the potential role of FoxO1 on Notch signaling in our 
experimental system. We were able to observe that induction of the Notch target gene, 
Hes1 by hyperglycemia (figure 11) in HDFs is cancelled when FoxO1 was specifically 
silenced by siRNA suggesting a FoxO1 mediation. However, further investigation is 
necessary to understand the exact underlying mechanisms of Notch activation by fringes 
and FoxO.
Notch signaling interacts as well with p53 pathway379. NICD1 is activated by p53276 and 
p53 is activated by hyperglycemia341. It is therefore tempting to propose this interaction 
as potential mediator of the hyperglycemia effect on Notch signaling.
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4.7  HIF-1 alpha and hyperbaric oxygen therapy (HBOT) in treatment of diabetic 
wounds (Paper IV)
Hyperbaric oxygen has been used as an adjuvant therapy for many years in the 
treatment of complicated diabetic wounds. However, the underlying mechanism is not 
clear. We show here that HBOT induces HIF-1 alpha stabilization. This effect takes 
place at later time points after exposure to high oxygen pressure, suggests that is not a 
direct effect of oxygen but of other different mechanisms. Radical oxygen species 
(ROS) excess during exposure to HBO could be such a mediator380 since ROS 
improve HIF-1 alpha stability and function 381. It is however difficult to accommodate 
the ROS impairment of PHDs with the VHL independent regulation noted in HBO 
exposure. However other potential VHL independent mediators could stabilize HIF in 
HBOT as HSP90107, RACK1 108, Mdm2 382 Jun activation domain-binding protein-1
(Jab1) 31 FOXO4 383 or GSK3 384.  HBOT effect is via HIF-1 since it stimulated 
proliferation of wild type MEFs (HIF+/+), but the proliferative effects were abolished 
in HIF deficient cells (MEFs  HIF-/-).
It has been shown that HBO stimulates the release of endothelial progenitor cells (EPC) 
from bone marrow that finally home in the wounds and contribute to angiogenesis and 
wound healing304. However, this process is defective in diabetes due to low levels of 
SDF-1 alpha, a cytokine that modulates the EPCs homing. Local application of SDF-1
alpha together with HBOT increases the healing rate in diabetic mice296,304,370. Taking 
into account that SDF-1 is a target gene for HIF-1370 and the importance of HIF-1 alpha 
in diabetic wound healing in mice (Paper I) we have studied the effect of combined 
local induction of HIF-1 alpha with HBO treatment. Indeed adenovirus mediated 
transfer of HIF-1 alpha improves the effect of HBOT on wound healing in db/db mice. 
In perfect agreement with the central role of HIF-1 alpha as inducer of much more other 
relevant target genes for wound healing above SDF-1, the transfer of HIF-1alpha was 
superior to the adenoassociated virus mediated transfer of SDF-1 alpha in potentiating 
the effects of HBO on wound healing in db/db mice (Figure 12).
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5  POINTS OF PERSPECTIVES
The focus of our investigation was to identify new pathogenic mechanisms relevant for 
the defective wound healing in diabetes. We have identified two new pathways that 
contribute to the repressive effect of diabetes on wound healing and could propose new 
therapeutic approaches.
The role of HIF, in diabetes was just emerging when this work started. We have further 
investigated the mechanisms behind the repressive effect of hyperglycemia on hypoxia 
induced HIF-1 alpha. We could show that hyperglycemia destabilizes HIF-1 alpha 
through a VHL dependent mechanism- Moreover we could show that hyperglycemia 
affects both transactivation domains of HIF but stabilization of HIF-ĮLVQHFHVVDU\DQG
sufficient for promoting wound healing in a diabetic environment.. We could make the 
proof of concept concerning the central role of HIF for defective wound healing in 
diabetes through improvement of healing in in an experimental model of diabetic 
wounds by using either chemicals that induce HIF or through direct adeno-virus 
mediated transfer of HIF. These results might offer the premises for conducting clinical 
studies on wound healing in patients with diabetes. DFX which we used efficiently in 
vitro and in vivo to induce HIF-1 alpha is already clinically approved for other 
indications. Moreover inhibitors of HIF-1 hydroxylases are developed, for other 
indications by several pharmaceutical companies. 
Important future issues are the identification of the critical residues that are sensitive to 
hyperglycemia-induced HIF-1 alpha destabilization and to identify the pathways 
activated by hyperglycemia that lead to HIF repression in diabetes. Both these strategies 
could suggest more specific future therapies. 
Hyperbaric oxygen therapy (HBOT) has been proposed as a medical treatment for 
diabetic foot ulcers. We demonstrated that HBOT activated HIF-1 alpha and contribute 
to diabetic wound healing. Moreover, we could show that local transfer of a stable form 
of HIF has an additive effect to HBOT improving wound healing in db/db mice. Further 
studies on the HBOT and HIF-1 alpha contribution in wound healing in patients with 
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diabetic foot ulcers will help to further tailor therapeutically use of potential 
combination between HBOT and HIF alpha local induction.
Notch signaling was identified as another important pathway deregulated by 
hyperglycemia with relevance for defective wound healing in diabetes. Notch pathway 
is highly important for several cell fate decisions-. We demonstrated that hyperglycemia 
could induce Notch signaling both in vitro and in vivo. Blockage of Notch signaling 
induced by hyperglycemia using gamma-secretase inhibitors (DAPT or L-658,458) 
resulted in positive effects on migration and angiogenesis in vitro, and improved wound 
healing in diabetic mice. Moreover, we could show that these effects were specific for 
diabetes, since treatment with either gamma-secretase inhibitors or DNA vaccine against 
Dll4 did not influence wound healing in non-diabetic mice. We could also identify the 
central pathogenic role of Notch1 in Notch dependent defect in wound healing in 
diabetes through loss of function genetic approaches (siRNA and cre/lox system).
These results offer the premises for the use of gamma secretase inhibitors in clinical 
studies in patients with DFU, as gamma secretase inhibitors have already been 
developed and studied in humans, for other indications. However, the potential use of 
specific Notch 1 inhibitors is of more interest in this context. Having in mind the 
interplay between HIF signaling and Notch signaling during development it would be 
highly interesting to further investigate the interaction between these systems in diabetes
in general and in diabetes wounds in particular.
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6  CONCLUDING REMARKS
HIF-1 alpha represent a potential therapeutic target for improving the defective wound 
healing process in diabetes:
x High glucose impairs HIF-1 alpha stability and function in vitro and in wounds 
in diabetic mice
x The repressive effects of high glucose involves a VHL-mediated degradation 
mechanism
x The increase of local HIF levels through blockade of the HIF hydroxylation or 
through direct HIF-1 alpha adenoviral transfer results in improvement of wound 
healing in diabetes.
x HBOT induces HIF-1 alpha and the combination of HBOT with local HIF-1
alpha stabilization reverses the negative effects of diabetic wound healing in 
mice.
x HIF stabilization is critical for improving defective wound healing in diabetic 
mice, activating all the essential steps of this process.
Hyperglycemia activates Notch signaling with repressive effect on wound healing in 
diabetes Hyperglycemia activates Notch signaling at different levels with negative 
effects on cell migration and angiogenesis
x Blocking overactive Notch signaling using gamma-secretase inhibitors rescues 
in vitro hyperglycemia repressed migration and angiogenesis, and improved 
wound healing in diabetic mice
x Notch1 is the main player of the Notch negative effect for wound healing in 
diabetes
In conclusion, we identified two new pathogenic mechanisms important for defective 
wound healing in diabetes. Our findings warrant development of specific therapeutics 
that address HIF and Notch signaling for improving the healing of diabetes wounds.
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